Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Diamorphine
Ayendi
Not routinely available
SMC (1172/16)
11/10/2023
Indication
Treatment of acute severe nociceptive pain in children and adolescents in a hospital setting. Diamorphine hydrochloride nasal spray (Ayendi) should be administered in the emergency setting by practitioners experienced in the administration of opioids in children and with appropriate monitoring.
Therapeutic Area
Central nervous system
Status Description
Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines
Formulation
720 microgram/actuation and 1600 microgram/actuation nasal spray
Comments
Link to Advice
Advice Published
08/08/2016
SMC Submission Type
Abbreviated
SMC Status
Accepted